MXPA01003207A - Propanolamine derivatives linked with bile acid used for treating disorders of the lipid metabolism - Google Patents
Propanolamine derivatives linked with bile acid used for treating disorders of the lipid metabolismInfo
- Publication number
- MXPA01003207A MXPA01003207A MXPA/A/2001/003207A MXPA01003207A MXPA01003207A MX PA01003207 A MXPA01003207 A MX PA01003207A MX PA01003207 A MXPA01003207 A MX PA01003207A MX PA01003207 A MXPA01003207 A MX PA01003207A
- Authority
- MX
- Mexico
- Prior art keywords
- bond
- compound
- alkyl
- amino acid
- pharmaceutical
- Prior art date
Links
- 239000003613 bile acid Substances 0.000 title claims description 11
- 230000037356 lipid metabolism Effects 0.000 title claims description 8
- 150000003152 propanolamines Chemical class 0.000 title abstract description 4
- 201000010099 disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 93
- 239000011780 sodium chloride Substances 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims description 43
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 230000000069 prophylaxis Effects 0.000 claims description 7
- -1 radical amino acid Chemical class 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 206010062060 Hyperlipidaemia Diseases 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229910006069 SO3H Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 26
- 239000002253 acid Substances 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 17
- 239000000047 product Substances 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 210000000110 Microvilli Anatomy 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 230000035693 Fab Effects 0.000 description 6
- WBWWGRHZICKQGZ-HZAMXZRMSA-N Taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N 1,2-dihydrobenzotriazol-4-one Chemical compound O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 210000003405 Ileum Anatomy 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(Z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000001419 dependent Effects 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 210000000941 Bile Anatomy 0.000 description 3
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 3
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000000968 intestinal Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrugs Drugs 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 101710006356 ACTI Proteins 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 229960005261 Aspartic Acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 101700046715 CSTI Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101700020566 DEFA4 Proteins 0.000 description 2
- 229940022766 EGTA Drugs 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 101710006353 IP3R Proteins 0.000 description 2
- 101700035656 ISOTI Proteins 0.000 description 2
- 101700035039 ITI Proteins 0.000 description 2
- 101700052013 ITR2 Proteins 0.000 description 2
- 101700068039 ITRP Proteins 0.000 description 2
- 210000000936 Intestines Anatomy 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 101700036939 MTI Proteins 0.000 description 2
- RINCXYDBBGOEEQ-UHFFFAOYSA-N Succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101700062451 TI Proteins 0.000 description 2
- 229960003080 Taurine Drugs 0.000 description 2
- BGHCVCJVXZWKCC-UHFFFAOYSA-N Tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2S)-1-(9H-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FJACZYDXMHRUJF-WCCKRBBISA-N 2-aminoacetic acid;(2S)-pyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.OC(=O)[C@@H]1CCCN1 FJACZYDXMHRUJF-WCCKRBBISA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102220390661 CDK13 C53H Human genes 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N Diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- LMBMDLOSPKIWAP-UHFFFAOYSA-N Embutramide Chemical compound OCCCC(=O)NCC(CC)(CC)C1=CC=CC(OC)=C1 LMBMDLOSPKIWAP-UHFFFAOYSA-N 0.000 description 1
- 229950009082 Embutramide Drugs 0.000 description 1
- 210000002615 Epidermis Anatomy 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000004051 Gastric Juice Anatomy 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 208000008384 Ileus Diseases 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000004212 Madhuca longifolia Species 0.000 description 1
- 235000005058 Madhuca longifolia Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229950003595 Mebezonium Iodide Drugs 0.000 description 1
- IXCKOXLJNNFOCM-UHFFFAOYSA-N N,N,2-triethylaniline Chemical compound CCN(CC)C1=CC=CC=C1CC IXCKOXLJNNFOCM-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- IEIMRKVTGUNYPS-RSLQBAFYSA-N OC1CN[C@H](C(O)=O)C1.OC1CCN[C@@H]1C(O)=O Chemical compound OC1CN[C@H](C(O)=O)C1.OC1CCN[C@@H]1C(O)=O IEIMRKVTGUNYPS-RSLQBAFYSA-N 0.000 description 1
- 229940100467 POLYVINYL ACETATE PHTHALATE Drugs 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229940066842 Petrolatum Drugs 0.000 description 1
- 240000005158 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 229960005190 Phenylalanine Drugs 0.000 description 1
- 229940068917 Polyethylene Glycols Drugs 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 Tetracaine Drugs 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- BHQCQFFYRZLCQQ-UTLSPDKDSA-N Ursocholate Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UTLSPDKDSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6S)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2R,3R,4S,5R,6S)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 239000002318 adhesion promoter Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960003692 aminobutyric acid Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 229930002877 anthocyanins Natural products 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HSUIVCLOAAJSRE-UHFFFAOYSA-N bis(2-methoxyethyl) benzene-1,2-dicarboxylate Chemical compound COCCOC(=O)C1=CC=CC=C1C(=O)OCCOC HSUIVCLOAAJSRE-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 125000001309 chloro group Chemical class Cl* 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FFLYUXVZEPLMCL-UHFFFAOYSA-N ethylchloranuidyl formate Chemical compound CC[Cl-]OC=O FFLYUXVZEPLMCL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MVFGXYPEQHIKIX-UHFFFAOYSA-M heptane;acetate Chemical compound CC([O-])=O.CCCCCCC MVFGXYPEQHIKIX-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000001050 lubricating Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- BFRGSJVXBIWTCF-UHFFFAOYSA-N niobium monoxide Inorganic materials [Nb]=O BFRGSJVXBIWTCF-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- UJJLJRQIPMGXEZ-UHFFFAOYSA-M oxolane-2-carboxylate Chemical compound [O-]C(=O)C1CCCO1 UJJLJRQIPMGXEZ-UHFFFAOYSA-M 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- CWPAAKNARYMZLM-UHFFFAOYSA-L trimethyl-[4-[[4-(trimethylazaniumyl)cyclohexyl]methyl]cyclohexyl]azanium;diiodide Chemical compound [I-].[I-].C1CC([N+](C)(C)C)CCC1CC1CCC([N+](C)(C)C)CC1 CWPAAKNARYMZLM-UHFFFAOYSA-L 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Abstract
The invention relates to substituted propanolamine derivatives and their pharmaceutically acceptable salts and physiologically functional derivatives. The invention relates to compounds of formula (I), wherein the radicals have the defined meanings, as well as their physiologically acceptable salts, physiologically acceptable derivatives and methods for their production. The compounds are suitable, for example, as hypolipidemic agents.
Description
PROPANOLAMINE DERIVATIVES LINKED TO BILIS ACIDS FOR THE TREATMENT OF DISTURBANCES IN LIPID METABOLISM
The invention relates to substituted propanolamine derivatives and pharmaceutically tolerated salts and physiologically functional derivatives thereof. Various classes of active compound have already been described for the treatment of adiposity and disturbances in lipid metabolism - polyrheric adsorbers such as for example, cholestyramine-benzothiacepmas (WO 93/16055) 1C) - bile acid dimers and conjugates (EP 0 489 423) - 4-am? no-2-ure? do-p? r? m? dm- 5 -carboxamias (EP 0 556 879) The invention was based on the object of providing additional compounds that exhibit a therapeutically valuable hypolipidomic action The invention, therefore, relates to compounds of formula 1
. _
where GS is a group of bile acid of the formula
Rl is a bond to X, OH, R2 is a bond to X OH, O- (Ct-C6) -alqu i lo NH-? C2-Cb) -alkyl-S03H, N (CH, j -CH2- CH2-SO, H NHÍ C, -C6 j -al? Ui lo-COOH
N (CH3) - (Cl-C,) -alkyl -COOH. with the proviso that R1 and P2 do not have the following meaning R1 and a bond to X and R2 a bond to X, R3, R4 independently of each other are H OH 0 X is - -AA, - X f-AA2 -L- -N | H 1 c a bond l, m, n independently of one another are 0 or 1 L is alkyl- (C? -Cb), phenyl AA?, AA2 independently of one another are an amino acid radical or an amino acid radical which is mono or polysubstituted by an amino acid protecting group, and pharmaceutically tolerated salts and physiologically functional derivatives thereof The preferred compounds of formula 1 are those in which one or more radicals has the following meaning GS in group of bile acid from the tormul-
R1 a bond to X OH, R2 a bond to X, OH, O- (d-Cb) -alkyl, NH- (C2-C6) -alkyl-S03H, N (CH,) -CH2-CH2-S03H , NH- (Cj-C-alkyl-COOH, N (CH3) - (-Cβ) -alkyl 1 -COOH, with the proviso that R1 and R2 do not simultaneously have the following meaning R1 a bond to X and R2 a link to X,
X or a bond 1, m, n independently of one another, 0 or 1, L alkyl- (C? -C6), phenyl AAi, AA2 independently of each other, an amino acid radical or an amino acid radical that is mono- or polysubstituted by a protecting group of amino acids and pharmaceutically tolerated salts and physiologically functional derivatives thereof Particularly preferred compounds of formula 1 are those in which one or more radicals has the following meaning GS a group of acid of bile of the formula
R1 a bond to X OH R2 a bond to X, QH. 0- (C, -Cb) -alkyl. NH- (C2-Cb) -alkyl-S3H. NH- (d-d) -alkyl 1 -COOH. with the proviso that R1 and R2 do not simultaneously have the following meaning. R1 a link to X and R2 a link to X
or a bond, 1, n independently of one another 0 or 1 L ali lo- i C? -C6) 'AA,. AA2 independently of one another are an amino acid radical or an amino acid radical which is mono- or polysubstituted by an amino acid protecting group, and pharmaceutically tolerated salts thereof. The term "alkyl" is understood to mean branched hydrocarbon chains or straight chain c, The term amino acids or amino acid radicals means the stereoisomeric forms, ie, D- or L- forms of the following compounds alanine glycine proline cistern histidine glutamine Q aspartic acid isoleucine arginma glutamic acid lysine serine phenylalanine leucma threonine triptofan methyna valine tyrosma asparagma ] _C | 2-ammoadipic acid 2-ammonium-2-butbutic acid 2-amynaadipic acid 3-ammonium-sobutypic acid-2-alanine acid 2-ammop-methyl acid 2-ammobutyric acid 2 , 4-d? Apunobutyr? Co acid 4-am? Nobutyr? Co desraosma or piperidic acid 2, 2-d? Am? Nop? Mél? Co acid 6-ammocapro? Co acid 2,3-d? Ammoprop? On 2-ammoheptane acid co-N-ethylglycine 2- (2-t-eml) -gl? c? na 3- (2-t? in? l) -alamine peni cylamine N-rnetylglycine 5 N-ethylaparagine N -methyloleucine hydroxymethyl 6-N-methylamine to hydroxylamine N-metilvane 3-hydroxy proline 4-hydroxy proline norleucine 5 isosmosm orni tubula allo-isoleucine acid 11-am? noundecano? co The amino acids abbreviated in accordance with the usual customary nomenclature (cf Schroeder, L? Bke Peptides Volume 1, New York 1965, pages Q XXII-XXIII Houben-Weyl, Methoden der Organischen Chemie
[Methods of Organic Chemistry] Volume XV / 1 and 2 Stuttgart 1974) The amino acid D-Asp is the D-form of aspartic acid The peptides are acidic amides of their chemical nature and dissociate into amino acids
- | _5 during hydrolysis The term amino acid protecting groups is to be understood as meaning appropriate groups with which the functional groups of the side chains of the amino acid radicals are protected (see for example TW Green, PGM Wuts Protective Groups in Organic Synthesis, 2nd Edition, John Wiley and Sons, New York 1991) Preferred amino acid protecting groups are t-butyloxycarbonyl (BOC) 5 9-fluorenylmethoxycarbonyl (Fmoc) benzyloxycarbonyl (Z), 2- (3 , 5-d? Methox? Phenyl) prop-2-? loxi carbon ilo (Ddz), methyl. t-butyl, triethyl and S-t-butyl t-butyl-laminocarbon The invention is further related to processes for the preparation of compounds of formula 1 which proceed in accordance with the following reaction equations (equations 1 to 4)
Equation 1
racematc 1 racomate splming
onanliomer Type IV compounds are obtained by reacting o-m- or -substituted types II with ketone III. The reaction can be carried out for example by mixing the two compounds by volume without a solvent and then heating, or in a suitable solvent, such as ethanol, tetrahydrofuran (THF), toluene, diglyme or tetradecane, at temperatures of 20aC to 150SC Keto compounds of type IV are reduced to hydroxy compounds of type V with NaBH "or other appropriate reducing agent in a suitable solvent , such as for example methane THF or THF / water at temperatures between -30aC and + 40aC Two mixtures of isomer (racemates) are usually obtained as the main product in the reduction The various racemates can be separated from each other by fractional crystallization or chromatography of silica gel The nitro group in compounds of type V can be reduced by known processes, such as for example catalytic hydrogenation with Pd or Pd-en- carbon and H2 in methanol Racemic compounds of type VI obtained d? in this way they can be further separated into their enanomers. The division of VI racemate into enantiomers of type VII can be carried out by chromatography on chiral column material or by means of methods known from the literature using optically active auxiliary reagents (cf J Org. Chem 44 1979 4891) Equation 2
VI or Vil
1 FmocAAOH 2 doprotoction
According to equation 2, the aromatic amines of type VI or VII (race ato or pure enanomer) can be reacted with an amino acid by known conventional peptide coupling processes to provide VIII derivatives. An appropriate process, for example, is to copulate with TOTU and triethylamine in DMF (for the literature see G Breipohl W omg EP 0460446. W Konig G Ereipohl P Pokorny M Birkner in E. Giral and D Anareu eEcs) Peptides 1990, Escom. Leiden, 1991 143-145) Radicals AAi and AA? they have the meaning provided under formula 1 The amino function of the amino acid ST provides with a protecting group for example Fmoc and the carboxylic acid Lico is unprotected In amino acids with functional groups in the side chain, these are protected accordingly, either temporarily during the synthesis or to remain in the compounds according to the invention to bring the amino function protecting group to the derivative VIII is for example divided in the case of Fmoc in a mixture of DMF and piperidma The conjugates of dipeptide IX they are obtained if starting the compounds of type VIII the reaction sequence (a) which couples an amino acid and (b) deprotection is repeated Equation 3
1 coupling reaction 2. hydrolysis
The bile acid derivatives of type X can be prepared from the acid ester of 3-am? No-b? 1 is linking with alkyl arylcarboxylic acids or derivatives thereof such as for example succinic anhydride by known processes (for example EP 0614908 EP 0489423) Compounds (X) are reacted with arninc compounds of type VI, VII VIII or IX by conventional peptide coupling processes. After the coupling reaction, compounds of type XI are obtained by hydrolysis of the alkyl ester function of part of the acid of bile Ecuac ón 4
Amino compounds of type VI, VII, VIII or XI can be reacted with the carboxylic acid function of bile acids. The known coupling processes of polypeptide are also used here, for example. copulating in the presence of TOTU and triet i lamina or with dicyclohexy Icarbodi imide hydroxybenzotriazole and triethylamine in THF. Compounds of type XII can be obtained by this process. Due to their superior solubility in water compared to the starting or base compounds, the pharmaceutically tolerated salts are particularly suitable for moderate applications. These salts should have a pharmaceutically tolerated anion or cation. The pharmaceutically tolerated acid addition salts of the according to the invention are salts of inorganic acids, such as hydrochloric, or hydrobromic, phosphoric, metaphosphobic, nitric, sulphonic and sulfuric acid, and of organic acids, such as, for example, acetic or benzenesulonic acid, benzoic acid, citric acid, etansul phonic, fumaric, gluconic, glycolic, isotonic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic. p-toluenesulfonic, tartaric, and tri-furanoic acid. The chlorine salt is particularly preferably used for modest purposes. The appropriate pharmaceutically tolerated basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and magnesium salts). calcium). Salts with an anion that is not pharmaceutically tolerated are also included within the scope of the invention as beneficial intermediates for the preparation or purification of pharmaceutically tolerated salts and / or for use in non-therapeutic applications for example, in in vitro applications. "physiologically functional derivative" used herein denotes any physiologically tolerated derivative of a compound of formula 1 d? according to the invention, for example an ester which, during administration to a mammal, such as for example, humans, is capable of forming (directly or indirectly) a compound of formula 1 or an active metabolite thereof Physiologically derived functional products also include prodrugs of the compounds according to the invention. These prodrugs can be
^ Metabolize in vivo a compound in accordance with the invention These prodrugs may or may not be active themselves. The compounds according to the invention may also be in various polymorphic forms, for example as amorphous or crystalline polymorphic forms. All polymorphic forms of the compounds according to the invention are included within the scope of the invention and are a further aspect of the invention. All references to "compound (s) according to formula (1)" below are related to compound (s) of the formula (1) as described above, and its salts, solvates and physiologically functional derivatives as described herein The amount of a compound according to the formula (1) which is necessary to achieve the effect The desired biological function depends on a number of factors, for example, the specific compounds selected, the intended use, the mode of administration and the clinical condition of the the patient In general, the daily dose is on the scale of 0 3 mg to 100 mg (typically 3 mg to 50 mg) per day per kilogram of body weight for example 3-10 mg / kg / day An intravenous dose, for example it may be on the scale from 0 3 mg to 10 mg / kg which can be appropriately administered as an infusion of 10 ng to 100 ng per kilogram per minute. The appropriate infusion solutions for this purpose may comprise, for example, 0 1 ng to 10 mg, typically from 1 ng to 10 mg per milliliter Individual doses may comprise, for example from 1 mg to 10 g of the active compound The ampules for injections in this manner may contain, for example from 1 mg to 100 mg and individual dose formulations for oral administration such as for example tablets or capsules may contain, for example from 10 to 1000 mg, typically from 10 to 600 mg. In the case of pharmaceutically tolerated salts , the weight data mentioned above are related to the weight of the benzothiazepma ion derived from the salt. For prophylaxis or treatment of the above-mentioned conditions the compounds according to the formula (1) can be used as the compound but preferably they are in the Form of a pharmaceutical composition with a tolerated excipient The excipient should of course be tolerated in the sense that it is compatible with the other constituents of the composition and is not harmful to the health of the patient. The excipient can be a solid or a liquid or both. , and preferably is formulated with the compound as a single dose for example as a tablet which can comprise from 0 to 95% by weight of the active compound Additional pharmaceutically active substances can also be present including additional compounds according to formula (1). The pharmaceutical compositions according to the invention can be prepared by one of the known pharmaceutical methods comprising essentially mixing the constituents with pharmacologically tolerated excipients. and / or auxiliaries The pharmaceutical compositions according to the invention are those which are suitable for oral rectal, topical peroral (for example sublingual) and parenteral (e.g. subcutaneous, intramuscular, mdermic or intravenous) administration even though the most appropriate mode of administration in each individual case it depends on the nature and severity of the condition to be treated and on the nature of the particular compound in accordance with the formula (1 j used) The coated formulations and sustained release formulations coated Also included within the scope of the invention Formulations that are resistant to acid and gastric play are preferred. Suitable coatings that are resistant to gastric juice include cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, and polymers. ammonia of methacrylic acid and methyl methacrylate The pharmaceutical compounds suitable for oral administration can be in the form of separate units such as for example capsules on chewable tablets or tablets each of which comprises a certain amount of the compound according to the formula (1) , as powders or granules as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil in water or water in oil emulsion. As already mentioned these compositions can be formulated by any suitable pharmaceutical method comprising a step in the than the active compound and the excipient (which ede comprising one or more additional constituents) are brought into contact. The compositions are generally prepared by uniform and homogeneous mixing of the active compound with a liquid and / or finely divided solid carrier, after which the product is configured if required. For example, a tablet can be prepared by pressing or stirring a powder or granules of compound optionally with one or more additional constituents. The pressed tablets can be prepared by tabletting the compound in the free-flowing form, such as for example a powder or granules. , optionally mixed with an inert diluent lubricating binder and / or one (or more) surfactants / dispersants, in an appropriate machine. The shaped tablets can be prepared by shaping the powdered compound that has been moistened with an inert liquid diluent in an appropriate machine. Pharmaceutical compositions that are suitable for administration n peroral (sublingual j include lozenges which comprise a compound according to formula (Ij with a substance sabopzante, usually sucrose, and gum arabic or tragacanth, and lozenges, comprising the compound in an inert base, such as gelatin and glycerol, or sucrose and gum arabic. Pharmaceutical compositions suitable for parenteral administration preferably include sterile aqueous formulations of a compound according to formula (1), which are preferably isotonic with the blood of the intended recipient. These formulations are preferably administered intravenously, even when the administration can also occur subcutaneously intramuscularly intramuscularly or intradermally, as an injection. These formulations can be prepared by example, by mixing the compound with water and making the resulting solution sterile and isotonic with blood. The injectable compositions according to the invention generally comprise from 0 to 5% by weight of the active compound. The pharmaceutical compositions suitable for rectal administration are of preferential a of the form of single-dose suppositories These can be prepared by mixing a compound according to formula (1) with one or more conventional solid excipients, for example cocoa butter, and introducing the formed mixture into a mold. The pharmaceutical compositions Suitable for topical application to the skin are preferably in the form of an ointment, cream lotion, paste, spray, aerosol or oil. The excipients that may be used are petrolatum, lanolin, polyethylene glycols, alcohols and combinations of two or more of these substances The active compound is generally present in a concentration of 0 1 to 15% by weight of the composition for example 0 to 2% Transdermal administration is also possible. Pharmaceutical compositions suitable for transdermal applications can be in the form of individual patches that They are suitable for long-term close contact with the epidermis of the patient. These parch is appropriately comprise the active compound in an optionally buffered aqueous solution, dissolved and / or dispersed in an adhesion promoter or dispersed in a polymer. An appropriate concentration of active compound is about 1% to 35%, preferably about 3% to 15%. As a particular possibility, the active compound can be released by electrotransport or iontophoresis, as described, for example, in Pharmaceutical Research, 2 (6) 318 (1986). The invention relates to compounds of formula 1 in the form of their racemates racemic mixtures and pure enanomers and their diastereomers and mixtures thereof Compounds of formula 1 and pharmaceutically tolerated salts and physiologically functional derivatives thereof are distinguished by favorable actions on lipid metabolism. Compounds can be employed by themselves or in combination with additional active lipid reduction compounds The compounds They are suitable for prophylaxis and, in particular for treatment of disturbances in lipid metabolism, in particular hyperlipidemia. Compounds of formula 1 are also suitable for influencing serum cholesterol levels and for prevention and treatment of artepoesclerotic symptoms. The following findings demonstrate the pharmacological activity of the compounds according to the invention The biological test of the compounds according to the invention was carried out by determining the inhibition of [3H] -taurocholate admission in brush border membrane vesicles of the ileum of rabbits Inhibition test was carried out as follows 1 Preparation of brush border membrane vesicles from the ileum of rabbits The preparation of brush border membrane vesicles from intestinal small intestinal cells was carried out by the method of precipitation called Mg2t Rabbits m New Zealand anthocyanins (2 to 2 5 kg body weight) were sacrificed by intravenous injection of 0 5 ml of T61lR) an aqueous solution of 2 5 mg tetracaine HCl 100 m embutramide and 25 mg mebezonium iodide The small intestine it was separated and rinsed with ice physiological saline solution The 7/10 terminal of the small intestine (measured in the oral-rectal direction) ie the terminal ileus, which contains the b + acid-dependent Na + transport system) was used for the preparation of the brush-edge membrane vesicles The intestines were frozen at -80 ° C in plastic bags under nitrogen For the preparation of the membrane vesicles the frozen intestines were thawed at 30 C in a water bath The mucosa was scraped and suspended in 60 ml of 12 mM Tris / HCl buffer (pH 7 l = / 300 mM mannitol, 5 mM EGTA / 10 mg / l of femylmethylsulfonyl fluoride / 1 mg / l of soybean bean trypsin inhibitor (32 U / mg) / 0 5 mg / l of bovine lung trypsin inhibitor 19193 U / mg) 5 mg / l of bacitracma After from the dilution to 300 ml with ice distilled water the mixture was made with an Ultraturrax (rod 18- IKA Werk Staufen Germany) at 75% of the maximum for 3 minutes, while it was cooled with ice After the addition of 3 ml of MgCl2 solution to the IM (final concentration of 10 mM), the mixture was left to rest ra 0CC for exactly 1 minute By adding Mg2 +, the ce cell membranes are aggregated, and precipitated with the exception of the brush edge membranes after centrifugation at 3000 xg (5000 rpm, SS-34 rotor) for 15 minutes , the precipitate was discarded and the supernatant containing the brush border membrane, was centrifuged at 48,000 xg (20,000 rpm, SS-34 rotor) for 30 minutes. The supernatant was discarded and the precipitate was rehomogenized in 60 ml of buffer 12. mM Tris / HCl (pH 7.1) / 60 mM of tol, 5 mM EGTA with a Potter lvejhem homogenizer (Braun, Melsungen, 900 rpm, 10 runs) After the addition of 0 1 ml of 1M solution of MgCl 2 and a Incubation time of 15 minutes at 0 ° C the ST mixture was centrifuged again at 3000 xg for 15 minutes. The supernatant was then centrifuged again at 48,000 xg (20,000 rpm SS-34 rotor) for 30 minutes. The precipitate was taken in 30 ml of buffer. 10 mM Tris / Hepes (pH 7 4) / 300 mM of mannitol and homogeneously resuspended by 20 runs in a Potter Elvejhem homogenizer at 1000 rpm After centrifugation at 38,000 xg (20,000 rpm, SS-34 rotor) for 30 minutes, the precipitate was absorbed in 0 to 2 ml of Tris buffer / Hepes (pH 7 4) / 280 M mannitol (final concentration 20 mg / ml) and was resuspended with the help of a tuberculin syringe with a 27-gauge needle. The vesicles were used directly for transport studies after preparation. or were stored at -196eC in 4 mg portions in liquid nitrogen. 2. Inhibition of the admission of [__] Na + -dependent taurocholate in brush border membrane vesicles of the ileum The admission of substrates in the above-described brush border membrane vesicles was determined by means of the technique called membrane filtration. lOul of the vesicle suspension (100 ug of protein) were pipetted as drops towards the wall of a polystyrene incubation tube / ll x 70 mm), which contained the incubation medium with the corresponding ligands (90 ul). incubation medium comprised 0 75 ul = 0 75 uCi [3H (G)] -taurocholate (specific activity 2 1 Ci / mmol) / 0 5 ul of 10 mM taurocholate / 8.75 ul of sodium transport buffer (10 mM Tris / Hepes (pH 7 4) / 100 mM of mam tol / 100 mM of Ncl) (Na-TB) or 8 75 ul of potassium transport buffer (10 mM Tris / Hepes (pH 7 4) / 100 M of mamtol / 100 mM KCl), (KT-Bj and 80 ul of the inhibitor solution in question, dissolved in a buffer of Na-T ot KT amp, depending on the experiment The incubation medium was filtered through a lead polyvinyl fluoride membrane filter (SYHV LO 4NS 0 45 um, 4 mm OR Millipore, Eschborn, Germany) The transport measurement was started by mixing the vesicles with the incubation medium The concentration of taurocholate in the incubation lot was 50 uM After the desired incubation time (usually 1 minute), transport was stopped by the addition of 1 ml of ice-cold stop solution (10 mM Tps / Hepes) (pH 7 41/150 mM KCl) The formed mixture was immediately removed by suction filtration under a vacuum of 25 to 35 mbar on a cellulose nitrate membrane filter (MEE 25)., 0 45 um, 25 mm diameter, Schleicher &; Schuell Dassell Alema al The filter was rinsed with 5 ml of frozen stop solution To measure the admission of the radioactively labeled taurocholate, the membrane filter was dissolved with 4 ml of the Quickszmg 361 scintillator (Zmsser Analytik GmbH, Frankfurt, Germany) and the radioactivity was measured by measurement is liquid scintillation in a TriCarb 2500 measuring device (Canberra Packard GmbH, Frankfurt, Germany) The measured values were obtained as dpm (decompositions per minute) after calibration of the apparatus with the help of standard samples and after correction of any chemiluminescence present. The control values were determined in each case in Na-T-B and K-T-B. The difference between the admission in Na-T-B and K-T-B provided the Na + -dependent transport content. That concentration of inhibitor at which the Na + -dependent transport content was inhibited by 50% - based on the control - was designated the IC50 Na +. The pharmacological data comprises a series of tests in which the interaction of the compounds according to the invention with the acid transport system of intestinal bile in the terminal small intestine were investigated. The results are summarized in Table 1 Table 1 shows measurement values of the inhibition of admission of [3H] -taurocholate in brush border membrane vesicles of ileum of rabbits The quotients of the values of IC5-- of the substance Reference materials such as tauroquendeoxycholate (TCDC) and the particular test substance are shown in Table 1 Compounds of Example Csotta-TCDC [umol) C50 -_- substanc? a [umol 1 3 1 51 1 k 1 59 2 d 0 56 2 e 1 96 4 0 50 7 0 15 8 0 91 9 2 02 10 1 63 11 1 96 12 2 58 13 0 56 14 1 52
The following examples serve to illustrate the invention in greater detail without limiting it to the products and embodiments described in the examples.
Example 1
366 ml of 15% strength n-butyllithium in n-hexane were added dropwise to 50 g (0.54 mol of picolma in 770 ml of tetrahydrofuran) at -55 ° C. The mixture was warmed to room temperature and cooled again to room temperature. -55 ° C 77 g of N-N-dimethylbenzamide (0.5-2 mole) in 570 ml of tetrahydrofuran were slowly added dropwise and the mixture was then warmed to room temperature and stirred for an additional hour after the addition of 550 nor of IN hydrochloric acid, the mixture was extracted with ethyl acetate (3x) and the organic phases were dried with MgSO, and evaporated. Distillation of the residue gave 47 g (47%) of product Boiling point 134-136aC / 0 23 mbar
b.
0 g (0 13 mol) of o-nor robenzaldehyde 12 5 g (0 13 mol) of 2-aminopy pdna and 0 3 g of p-toluensulonic acid were heated under reflux in 150 ml of toluene for 2 hours. 5 hours, using a water separator The solution was cooled and the formed precipitate was filtered off with suction and dried. Yield 18 1 g (60%) of product Melting point 93-95sC C? 2HgN302 (227) MS (FAB) ) i 18 M + H *
12.0 g (61 mmol) of the ketone of Example 1 a and
. 0 g (66 mmol) of the emulsion of Example 1 b were heated in a steam bath for 45 minutes. The reaction mixture was dissolved in ethanol, while it was quenched. After cooling, the precipitate was filtered off with suction and It was recrystallized from ethanol. Rend imi ent 11 8 g (46%) of product C25H20N < O3 (2 4 2 HS (FAB) 425 M + H *
. 0 gi 18 8 mmol) of the sample compound was dissolved in 300 ml of tetrahydro tur anion water 10 1 4 67 g of sodium borohydride were added and the mixture was stirred at room temperature for 2 hours The solution was then evaporated 100 ml of 2N hydrochloric acid were added to the residue and the mixture was heated in a steam bath until everything had dissolved. After cooling the solution was made basic with NaOH solution and extracted with ethyl acetate ( 2x) The organic phases were dried with MgSO 4 and evaporated. The residue was chromatographed on silica gel and heptane / ethyl acetate 1 lj. Two racemic compounds were obtained as the product fraction 3 9 g (48%) of racemate not polar (Example 1 d / 1) C25H22N < 03 (426 2) MS (FAB) 427 M + H4 2a Fraction 2 5 g (31%) polar racemate (Example 1 d / 2) C2SH22N403 1426 2) MS (FAB ) 427 M + H '
2 g (5.86 mmol) of the polar n racemate of Example 1 d / 1 were dissolved in 300 ml of methanol, approximately 20 mg of 10% Pd / C were added and hydrogenation was carried out under an atmosphere of H2 at room temperature. The catalyst was separated by filtration and 1-solution was evaporated. The residue was chromatographed on silica gel (n-heptane / ethyl acetate 7 13) Yield 1 9 g (82%) of product C25H2, N, 0 '396 22 j MS i FAB j 397 M + H '(+) -ananmer (Example 1 f / 2)
100 mg of the racemic compound of Example 1 and ST were separated into the enanomers by HPLC in preparation The separation was carried out on a CSO-Chiralpak column (Daicel, Dusseldorf) with 4: 1 n-hexane / ethanol. 40 mg of the (-) - enanomer (Example 1 f / l) was obtained as the first fraction and 40 mg of the (+) - enanomer (Example 1 f / 2) was obtained as the second fraction
9-
4 0 g (10 1 mmol) of the ammo compound of Example le (non-polar racemate), 4 85 g (10 3 mmol) of N-Fmoc-D-Lyx (BOC) OH 4 0 g (12 2 mmol) of TOTL and 2 7 ml d? Triethylamine was dissolved in 300 ml of dimethyl formamide and the solution was stirred at room temperature for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate (2 x). The organic phases were dried (MgSO.l and evaporated). The residue was dissolved in 150 ml of dimeti-formamide / piperidine 2 1 to separate the Fmoc group and the stir-ST solution at room temperature for 1 hour. Poured into water and extracted with ethyl acetate (3 x) The organic phases dried (MgSO) and evaporated. Chromatography on silica gel (methylene chloride / methanol 9 1) yielded 4.0 g (63.5%) of product C36H4, NbO, (624 3) M5 (FAB) 625 M + H *
.0 g (11 86 mmol) of 3beta-ammocolic acid methyl ester (European Patent Application EP 0614908) 13 g (13 mmol of succinic anhydride and 16 ml of triethylamine were dissolved in 75 ml of t? The residue was dissolved in water and the solution was acidified with hydrochloric acid and extracted with ethyl acetate (3 x). The organic phases were dried (MgSO 4) and the solution was stirred at room temperature for 1 hour. «) And evaporated Yield 5 8 g (94%) C2 <, H < 7N07 (521 3) MS (FAB) 528 M * Ll *
4.0 g (6.4 mmol) of the compound of Example 1 g 3.45 g (6 6 mmolj of the bile acid derivative of Example 1 h 1 2 ml of triethylamine 2 16 g '16 mmol) of hydroxybenzotpazoi and 2 56 g of di The hydroxylcarbodimide (12 4 mmolj) was dissolved in 250 ml of tetrahydro turan and the solution was stirred at room temperature for 5 hours. The mixture was evaporated and the residue was dissolved in ethyl acetate and the solution was washed with NaHCO 3 solution. The organic extracts were dried (MgSO,) and evaporated. Chromatography on silica gel (methylene chloride / methanol 19 1 then 9 1) gave 3 1 g (43%) of product C6SHß, N7O10 f 1127 7) MS (FAB) 1134 7 M + Ll *
3 1 g (2.75 mmol) of the methyl ester of Example 1 i were dissolved in 200 ml of ethanol 31 ml of NaOH solution were added and the mixture was stirred at room temperature for 5 hours. The mixture was evaporated and the residue was evaporated. dissolved in water was added NaH2PO solution < saturated The mixture was extracted with ethyl acetate (2 x) and the organic phases were dried over MgSO 4 and evaporated The crude product was chromatographed on silica gel (methylene chloride / methanol 4 1) Yield 2 25 g (73%) ) C64Hß 7? 10 (1 1 1 3 7) MS Í FAB) 1 1 2 0 7 M + L i *
0 48 g of ethyl chloroformate were added to 1 5 g (1 35 mmol 1 of the compound of Example i / 0 81 ml of triethylamine at 0 ° C and the mixture was stirred for 10 minutes. Then 0.6 g of taurine dissolved in 30 ml was added. ml of 0 1 N NaOH solution and the mixture was stirred at room temperature for 24 hours. The mixture was evaporated, the residue was dissolved in a little water and the solution was poured into saturated NaHjPO solution. The mixture was extracted with ethyl acetate. Ethyl (3x) and the organic phases were dried with MgSO, and evaporated. After chromatography on silica gel (methylene chloride / methanol 4 1, then methanol) 0 9 g (60%) of taurine conjugate were obtained C66H, 2Nß012S (1270 7) MS (FAB) 1243 6 M + Na *
Example
2 5 gf 31 mmol) of the ammo compound of Example 1 e (non-polar racemate), 2 2 g (6 52 mm lj of Fmoc-L-proline, 2 5 g (762 mmol) of TOTU and 1 7 ml of triet The film was dissolved in 100 ml of dimethyl formamide and the solution was stirred at room temperature for 3 hours. The reaction mixture was evaporated in half, water was added and the mixture was extracted with ethyl acetate (3 x). The organic phases were dried over MgSO, and evaporated. After chromatography on silica gel (ethyl acetate / neptan 7 3), 35 g of 5% product were obtained. This intermediate product protected with Fmoc (3.6 g) was obtained. dissolved in 110 ml of pipepdine / DMF 1 10 and the solution was stirred at room temperature for 1 hour
The mixture was evaporated and the residue was chromatographed on silica gel (methylene chloride / ethanol 19 1 then
9: 1) Performance 1 8 g (72 5%) C3oH31N50? (4 9 3 2) MS (FAB) 4 9 4 M + H *
Example 2 b / 1 Example 2 b / 2 1 7 g (3.44 mmol) of compound d ^ l Example _ were stirred with 1 4 g (3 61 mmol) of Fmoc-L-femlala na 1 9 g 15 80 mmol) of TOTU and 10 ml of triethylamine in 150 ml of DMF at room temperature for 4 hours The reaction mixture was evaporated and the residue was chromatographed on silica gel (ethyl acetate, n-heptane 4 1). Two fractions were obtained. fraction 1 28 g (43%) of non polar polar diastereomer (Example 2 b / 1) Cs «HSoKA (862 4) MS (FAB) 863 4 M + H * 2a fraction 0 82 g (28%) of diather polar (Example 2 b / 1) C5 H5oN605 (86 2 4) MS (FAB) 8 6 2 4 M + H *
0 8 g (0.93 mmol) of the compound of Example 2 b / 2 were dissolved in 33 ml of DMF / piper id 10.1 and the mixture was stirred at room temperature for 1 hour. After evaporation, the residue was chromatographed on silica gel. silica (methylene chloride / methanol 19 1. then 9: 1) Yield 0 35 g (59%). C39H < oNb? 3 (640 3) MS (FAB) 641 3 M + H * d.
O 5 g (O 78 mmol) of the compound of Example 2 c and 0 45 g (0 86 mmol) of the bile acid derivative of Example 1 h were reacted by the process described for Example 1 i 0 38 g ( 43%) of product C6? H85N709 11143 6) MS (FAB) 1144 6 M + H *
0 31 gl 0 27 mmol) of the methyl ester dex Example 1 d were dissolved in 30 ml of ethanol, 3 ml of 1N NaOH solution was added and the mixture was stirred at room temperature for 12 hours. The reaction mixture was evaporated and the residue is chromatographed on silica gel (methylene chloride / methanol 4 1). Yield 220 mg (72%) CMHUNJO, (1129 6) MS (FAB) 1130 6 M + H * Example
0 3 g (0 78 mmol) of 3- (4-ammofe 1) -1- pheny 1-2-p? R? D? N-2-? L-3- (p? R? D? N-2 -? lam? no) -propan-l-ol (preparation analogously to Example le), 0 34 g (0 83 mmolj of ursocholic acid or 34 g (2 52 mmol i ae hydroxybenzotriazole or 41 g (2 mmol) of Dichlohexylcarbodumide and 15 ml of triethylaniline were stirred in 50 ml of tetrahydrofuran at room temperature for 2 days. When the reaction was complete, the solids were filtered off. The solution was evaporated and the residue chromatographed on silica gel. methylene / methanol 9 1 then 17 3) 0 33 g (55%) of product C49H62N405 (786 51 MS (FAB) 787 5 M + H * were obtained. Examples 4 to 14 were obtained from rranera analogous to Examples 1 to 3, starting from the corresponding starting compounds Example 4
d ^ N (787 1) MS (FAB) 788.1 M + H * Non-polar diastereomeric example
C53H67N, 07, 8 & 6 MS.'FAB) 887 2 M + H *
Example Cs4H6, N07 (900 2) MSiFABl 901 2 M + H *
C53H - 507 (886 2) MS (FAB) 887 2 M + H *
C53H67N507 (886 2) MS (FAB) 887.2 M + H *
Example
CsoHßiNjOß (1028 4) MS (FAB) 1029 4 M + H *
Example 10
C59H79N70B (1014.3) MS (FAB) 1015.3 M + H *
E j a lo 11
d7H83 70c) (1130.g) MS (FAB) 1031.5 M + H *
Example
C64Hß7N, 0, c 11114 4) MS (FAB) 1115 4 M + H *
Example 13
CsßHßsNjO, [1144 5) MS (FAB) 1145 5 M t-H *
Example 14
CßsH? ONßO ,, (1171.5) MS (FAB) 1172 5 M + H *
Claims (1)
- CLAIMS A compound of formula 1 where GS is a group of bile acid of the formula. R1 is a bond to X OH, R2 is a bond to X OH, O- (dd) -al qui lo Mh- (C2-d) -alkyl-S03H, Ni CH3) -CH, -CH, -S03H , NH- C C, -Ce) -a lchi 1-CCOH N (CH3) - (C, -Cβ) -a 1 qu 11 -COOH - so ¬ with the proviso that R1 and R2 do not simultaneously have the following meaning R1 a bond to X and R2 a bond to X, R3, R < independently of one another are H OH, or a bond, 1, m, n alkyl- (C? -C6). phenyl, AAi, AA2 independently of one another are an amino acid radical or an amino acid radical which is mono or polysubstituted by an amino acid protecting group, and pharmaceutically acceptable salts and physiologically functional derivatives thereof 2 - A compound of the formula 1 in accordance with claim 1 wherein GS is a bile acid group of the formula R1 is a bond to X, OH, R2 is a bond to X, OH, O- (dd) -alkyl, NH- (C2-C6) -alkyl-SO3H, N (CH3) -CH2-CH2-S03H, NH- (dd) -alkyl-COOH; N (CH3) - (d-C6) -alkyl-COOH, with the proviso that R1 and R2 do not simultaneously have the following meaning R1 a bond to X and R2 a bond to X; P 0 X is (-AAH, AA2J- -L-u N- or a bond, 1, m, n independently of one another are 0 or 1 L is alkyl- (d-C6), femlo, AAi, AA2 independently one on the other are a radical amino acid or an amino acid radical which is mono- or polysubstituted by an amino acid protecting group, and pharmaceutically tolerated salts and physiologically functional derivatives thereof 3 - A compound of formula 1 according to claim 1 or 2, where GS is a group of bile acid of the formula R1 is a bond to X, OH: R2 is a bond to X, OH, O- (C, -C6) -alkyl, NH- (C2-d) -alkyl-S03H, NH-> C, -C6 ) -alk 1 -COOH: with the proviso that R 'and R2 do not simultaneously have the following meaning R1 a bond to X and R2 a bond to X:. or a link: 1, m. n independently of one another are 0 or 1; L Alkyl of (dd) AAL AA2 independently of one another is an amino acid radical or an amino acid radical which is mono- or polysubstituted by an amino acid protecting group: and pharmaceutically tolerated salts thereof 4 - A pharmaceutical product comprising one or more than the compounds according to one or more of claims 1 to 3 - A pharmaceutical product comprising one or more of the compounds according to one or more of claims 1 to 3 and one or more lipid-lowering active compounds 6 - A compound according to one or more of claims 1 to 3 for use as a pharmaceutical for the prophylaxis or treatment of disturbances in lipid metabolism 7 - A compound according to one or more of claims 1 to 3, for used as a pharmaceutical for the treatment of hyperlipidemia 8 - A compound according to one or more of claims 1 to 3 for use as a pharmacist for the prophylaxis or treatment of arteriosclerotic symptoms 9 - A compound according to one or more of claims 1 to 3, in combination with at least one additional lipid-reducing active compound for use as a pharmaceutical for prophylaxis or treatment of disturbances in lipid metabolism 10 - A compound according to one or more of claims 1 to 3, in combination with at least one additional lipid-reducing active compound as a pharmaceutical for treatment of hyperlipidemia 11 - A compound in accordance with a or more of claims 1 to 3, in combination with at least one additional lipid-reducing active compound as a pharmaceutical for the prophylaxis or treatment of arteriosclerotic symptoms. 12 - A process for the preparation of a pharmaceutical comprising one or more of the compounds according to one or more of claims 1 to 3Jt. , which comprises mixing the active compound with a pharmaceutically acceptable excipient and bringing this mixture to an appropriate form for administration. The use of a compound according to one or more of claims 1 to 3, for the preparation of a pharmaceutical for the prophylaxis or treatment of disturbances in lipid metabolism 14 - The use of a compound according to one or more of claims 1 to 3 for the preparation of a pharmaceutical for treatment of hyperlipide ia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19845403.1 | 1998-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA01003207A true MXPA01003207A (en) | 2002-02-26 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2345369C (en) | Aryl-substituted propanolamine derivatives, their preparation, pharmaceuticals comprising them, and their use | |
US5428182A (en) | Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals | |
US5512558A (en) | Nor-bile acid derivatives, processes for their preparation and the use of these compounds as medicaments | |
CZ113594A3 (en) | Tetrazole derivatives of bile acids, process of their preparation and use of said compounds as medicaments | |
AU4108700A (en) | 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof | |
HU213395B (en) | Process for producing bile-acid derivatives and pharmaceutical compositions containing the same | |
WO2011025849A1 (en) | Processes for preparing protease inhibitors of hepatitis c virus | |
EA016199B1 (en) | Compounds and compositions as channel activating protease inhibitors | |
AU757366B2 (en) | Propanolamine derivatives linked with bile acid used for treating disorders of the lipid metabolism | |
US6596728B1 (en) | Substituted 1,3-diaryl-2-pyrid-2-yl-3-(pyrid-2-ylamino)propanol derivatives, process for their preparation, pharmaceuticals comprising these compounds and their use | |
MXPA01003207A (en) | Propanolamine derivatives linked with bile acid used for treating disorders of the lipid metabolism | |
CN100467480C (en) | Nitrate derivative of bile acid and its medical use | |
KR20030010575A (en) | 4-Benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use | |
US3060205A (en) | Process for preparation of 3-amino-1, 3, 5(10)-estratriene derivatives | |
WO2021033766A1 (en) | Lithocholic acid derivative having vitamin d activity | |
WO1996000230A1 (en) | Process for the manufacture of 3-amino-substituted glycosylated bile acids | |
CZ20011151A3 (en) | Propanolamine derivatives linked with bile acid used for treating disorders of the lipid metabolism | |
TW202346308A (en) | Salt form and crystal form of biphenyl compound as immunomodulator and method for preparing same | |
MXPA01003145A (en) | Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof |